WILMINGTON, DE — The European Commission has approved Zynyz (retifanlimab), developed by Incyte (Nasdaq: INCY), in ...

Female patient talking to doctor. There was no significant difference in event-free survival between the carboplatin-containing arms. Adding carboplatin to neoadjuvant paclitaxel significantly ...

This trial is looking at a new way of giving carboplatin chemotherapy called adaptive therapy. It is comparing this to having standard carboplatin chemotherapy for ovarian cancer. It is for women ...

New York, NY (August 20, 2025) – A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin ...

SAN ANTONIO — The addition of carboplatin to a standard neoadjuvant chemotherapy regimen significantly improves disease-free or event-free survival in patients with early-stage triple-negative breast ...

A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report. This is an ASCO Meeting Abstract ...

Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors Further trials are warranted that evaluate adding a 10 mg dose of ...

An analysis of national data found that short-term mortality was not impacted for patients with advanced cancers during the shortage of the generic platinum chemotherapy drugs cisplatin and ...